Jubilant Pharma

Jubilant HollisterStier LLC, an arm of Jubilant Pharmova Ltd, will invest USD 300 million by FY28 in the US to double its sterile injectable manufacturing capacity, with President Donald Trump's tariffs accelerating its original plans, company CEO - CDMO Sterile Injectables, Chris Preti, said on Friday. The company has launched its new sterile fill and finish line -- the third at its Spokane manufacturing facility in Washington, US, set up at an investment of USD 132 million, Preti told PTI. "Our overall investment is almost USD 300 million at our Spokane facility. This is the first of the two phases ... This USD 132 million is phase one, which is our third line," he said. Preti further said, "This will bring an additional 50 per cent of capacity in the US that is available now and then, the additional investment, totaling USD 300 million in all, will be actually completed by the end of fiscal year 2028 which will bring on another 50 per cent of additional capacity." On the company

Jubilant Pharmova shares rose after its board approved the slump sale of its API business to wholly-owned subsidiary, Jubilant Biosys.

Revenue rose 9 per cent to Rs 1,814 crore, lifted by the radiopharma segment's nearly 12 per cent growth this quarter

Shares of Jubilant Pharmova surged 12 per cent on the BSE in Friday's intra-day trade to hit a new high of Rs 1,169.55, in an otherwise subdued market.

Jubilant Pharmova share price rose as much as 4.2 per cent, touching its all time high at Rs 1060.15 per share on the BSE in early hours of Wednesday's intraday deals

Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.

Jubilant Pharmova Ltd on Friday reported a multi-fold jump in consolidated net profit to Rs 481.8 crore boosted by gain on sale on investment in associate firm SOFIE Biosciences Inc USA. The company had posted a consolidated net profit of Rs 6 crore a year earlier, Jubilant Pharmova said in a regulatory filing. Consolidated total revenue from operations stood at Rs 1,731.7 crore as against Rs 1,586.9 crore in the year-ago period, it added. The exceptional items in the first quarter of the current fiscal include net income of Rs 669.2 crore following sale of investment in SOFIE, expenses of Rs 91.6 crore accrued due to closure of manufacturing operations of solid dosage formulation facility at Salisbury, Maryland, USA; Rs 95.3 crore provision for slow moving inventory in respect of solid dosage formulation business and litigation cost of Rs 50 crore among others. During the quarter, Jubilant Pharmova said its radiopharmaceuticals segment revenue grew 28 per cent year-on-year to Rs 2

Revenue from segments that make copycat drugs and medicines used for allergy immunotherapy rose 0.8% and 14%, respectively, during the quarter

Apar Industries, CESC, Glenmark, Jubilant Pharma and Power India are trading in overbought zone; charts suggest bias to remain positive as long as these support levels hold.

Jubilant Pharma had invested $25 million in Sofie Biosciences in November 2020 and now plans to exit its investment completely

Jubilant Pharmova Ltd on Wednesday reported an 87 per cent decline in consolidated net profit at Rs 6 crore in the first quarter ended June 30, impacted by higher expenses. The company had posted a consolidated net profit of Rs 46.8 crore in the same period last fiscal, Jubilant Pharmova said in a regulatory filing. Consolidated total revenue from operations were at Rs 1,586.9 crore, as compared to Rs 1,451.7 crore in the year-ago period, it added. Total expenses in the first quarter were at Rs 1,568.9 crore, as compared to Rs 1,393.8 crore in the corresponding period a year ago. Among various segments, Jubilant Pharmova said the radiopharmaceuticals vertical clocked a revenue of Rs 204 crore in the first quarter, while the radiopharmacies registered Rs 487 crore revenue. The generics business had a revenue of Rs 202 crore and the contract development and manufacturing organisation (CDMO) API segment had posted revenue of Rs 177 crore.

The United States Food and Drug Administration (US FDA) has classified its inspection of the company's Montreal Canada contract manufacturing (CMO) facility as Official Action Indicated (OAI)

Rating agency foresees firm's financial leverage worsening as a rise in capex will coincide with lower profitability

While the term loan and bonds aggregate to USD 350 million, about Rs 2,787 crore, the company is raising another tranche of USD 50 million (about Rs 400 crore) for capital expenditure.

Drug firm Jubilant Pharmova on Friday reported a consolidated net profit of Rs 160.49 crore from continuing operations for the quarter ended June 30, 2021. The company had posted a net profit of Rs 35.39 crore for the year-ago period, Jubilant Pharmova said in a regulatory filing. Revenue from continuing operations stood at Rs 1,634.65 crore in the quarter under review. It was Rs 1,156.07 crore in the same period a year ago, it added. Figures for the quarter are not comparable with previous periods since the Life Science Ingredients business was demerged with effect from February 1, 2021 pursuant to the composite scheme of arrangement during the previous year, the filing said. "During this quarter, in addition to YoY increase, we also reported sequential improvement in the specialty pharma segment with gradual recovery across radiopharmaceuticals, radiopharmacy and allergy business," Jubilant Pharmova Chairman Shyam S Bhartia and Co-Chairman & MD Hari S Bhartia said in a ...

Indian drug firms like Marksans Pharma, Aurobindo Pharma, Zydus and Jubilant are recalling products in the US market, as per the latest enforcement report by the USFDA

Company's product is a generic version of Daiichi Sankyo's Azor

Shares of Jubilant Life Sciences were trading 1.89 per cent higher at Rs 601 on BSE